Form 4: Tourmaline Bio Director Sells Shares in Novartis Merger

Tourmaline Bio Director Parvinder Thiara disposed of all common stock and stock options as part of the company's acquisition by Novartis AG for $48.00 per share.

Summary

• Parvinder Thiara, a Director of Tourmaline Bio, Inc. (TRML), reported the disposal of all beneficially owned common stock and employee stock options.
• The transactions occurred on October 28, 2025, as a result of Tourmaline Bio's merger with Novartis AG.
• Under the merger agreement, each common share was acquired for $48.00 in cash.
• Outstanding unexercised stock options were canceled and converted into a cash payment equal to the difference between the $48.00 merger consideration and the option's exercise price, multiplied by the number of shares.

Sentiment

Score: 8

Explanation: The filing reports the successful completion of a merger, resulting in a cash payout for shareholders and option holders, indicating a positive financial outcome.

Positives

• Shareholders received a cash payout of $48.00 per common share as part of the merger.
• Employee stock options were converted into cash, providing value to option holders based on the merger consideration exceeding their exercise prices.

Future Outlook

NA

Industry Context

This announcement reflects the completion of Tourmaline Bio's acquisition by Novartis AG, indicating ongoing consolidation within the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: Received $48.00 cash per share, indicating a successful exit from their investment.
• Employees (with options): Received cash for their vested stock options, realizing value from their equity holdings.

Key Dates

Keywords

Tourmaline Bio, TRML, Novartis, Merger, Acquisition, Form 4, Insider Transaction, Stock Option, Director